The new Novartis Pavillon on the Novartis Campus in Basel is home to the interactive exhibition “Wonders of Medicine” and many other exciting offers.

The new Novartis Pavillon on the Novartis Campus in Basel is home to the interactive exhibition “Wonders of Medicine” and many other exciting offers.

The new Novartis Pavillon on the Novartis Campus in Basel is home to the interactive exhibition “Wonders of Medicine” and many other exciting offers.

Novartis has created a sophisticated process for manufacturing CAR T Cell Therapies. Novartis CAR-T Cell theapy is developed using the patient's own T-Cells which are part of the body immune system and play a central role in fighting disease.

An animated overview of the science behind CAR-T cell therapy.

Chronic myeloid leukemia, or CML, is a cancer of the blood and bone marrow in which the body overproduces white blood cells. 

Our goal is to change the practice of medicine for patients around the world, including previously undeserved populations in developing regions.

Acute lymphoblastic leukemia (ALL) is a cancer of the blood and lymphocytes, and is a common cancer diagnosis in children.

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphocytes.Leukemia, a cancer of the blood, begins when normal blood cells change and grow uncontrollably. Acute lymphocytic leukemia is a cancer of the lymphocytes, a type of white blood cell involved in the body’s immune system.

While there are many different sub-types of non-Hodgkin lymphoma (NHL), each are unique in how they present in patients and how they should be treated. Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing), complex and difficult- to-treat form of NHL. NHL refers to a group of cancers of the lymphatic system that develop from the lymphocytes, a type of white blood cell involved in the body’s immune system.

Migraine can have up to four distinct phases—premonitory (or prodrome), aura, headache and post-drome— and each of them has many potential symptoms.

Hospitalization provides an opportunity for physicians to optimize heart failure treatment to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve outcomes for patients living with heart failure.